Of note, high Glut5 expression was found to be associated with a poor patient outcome for OSCC, prostate cancer and colorectal cancer patients; while the difference of the survival duration is not statistically significant for glioma patients. This evidence concerns the gene SLC2A5 and colorectal cancer.